You have been diagnosed with Non-Hodgkins Lymphoma, and when you asked why this happened to you, the answer you likely received was incomplete. Perhaps your doctor mentioned bad luck, or genetic factors, or simply acknowledged that the causes are not fully understood. That answer is technically accurate but profoundly insufficient when you are facing a cancer diagnosis and trying to understand how your life led to this moment.
The truth is that researchers have identified multiple documented causes of Non-Hodgkins Lymphoma. Some of these causes are corporate products with extensive litigation histories. Others are medical conditions, infections, or genetic factors with no legal dimension whatsoever. What you deserve is the complete picture of what the scientific literature actually shows, presented with the same rigor regardless of whether there is a corporation to hold accountable.
This article provides that complete picture. We have reviewed the epidemiological studies, the toxicology reports, the internal corporate documents that emerged in litigation, and the peer-reviewed medical research. What follows is everything the research shows about what causes Non-Hodgkins Lymphoma, organized so you can understand both the biological mechanisms and your own potential exposures.
The Research-Based Causes of Non-Hodgkins Lymphoma
Non-Hodgkins Lymphoma is not a single disease but rather a group of blood cancers that originate in the lymphatic system. The causes are multiple and sometimes overlapping. Some exposures create direct DNA damage in lymphocytes. Others cause chronic immune stimulation that increases the rate of cell division and therefore the opportunity for cancerous mutations. Still others suppress immune surveillance, allowing cancerous cells to proliferate unchecked.
The documented causes fall into several categories: chemical exposures with corporate sources, infectious agents, immune system disorders, medical treatments, genetic predispositions, and lifestyle factors. Each of these has different levels of evidence, different biological mechanisms, and different implications for understanding your own diagnosis.
Glyphosate Herbicide Exposure
Glyphosate is the active ingredient in Roundup and numerous other herbicides. It is the most widely used agricultural chemical in human history, with approximately 300 million pounds applied annually in the United States alone. For decades, Monsanto (now owned by Bayer) marketed glyphosate as safe enough to drink, and regulatory agencies accepted those assurances.
The biological mechanism linking glyphosate to Non-Hodgkins Lymphoma involves oxidative stress and DNA damage in lymphocytes. Glyphosate generates reactive oxygen species that overwhelm cellular repair mechanisms. It also disrupts the shikimate pathway in gut bacteria, potentially compromising immune function. A 2019 meta-analysis published in Mutation Research reviewed all available epidemiological studies and found that individuals with high cumulative exposure to glyphosate-based herbicides had a 41 percent increased risk of Non-Hodgkins Lymphoma.
What Monsanto knew is now a matter of public record due to litigation. Internal emails and documents revealed that company scientists were aware of studies showing genotoxic effects as early as the 1980s. Senior executives discussed ghostwriting supposedly independent scientific reviews. Regulatory affairs staff strategized about discrediting unfavorable research. One internal email from a Monsanto toxicologist stated that the company could not claim that Roundup had been tested for carcinogenicity when in fact it had not.
The litigation history is extensive. As of 2024, Bayer has faced over 100,000 claims and paid out more than 10 billion dollars in settlements and verdicts. Juries in California, Missouri, and other states heard evidence about what the company knew and awarded both compensatory and punitive damages. Agricultural workers, landscapers, groundskeepers, and home gardeners have all been affected.
Benzene Exposure
Benzene is a clear, colorless chemical compound used in the production of plastics, lubricants, dyes, detergents, drugs, and pesticides. It is also a natural component of crude oil and gasoline. Workers in petroleum refining, chemical manufacturing, rubber production, and shoe manufacturing have historically faced occupational exposure.
The mechanism is well established. Benzene is metabolized in the liver and bone marrow into reactive metabolites that bind to DNA and proteins. These metabolites cause chromosomal aberrations in blood-forming cells. The National Toxicology Program has classified benzene as a known human carcinogen since 1980. A 2009 study in the Journal of Occupational and Environmental Medicine followed 75,000 workers in China and found a dose-response relationship between benzene exposure and lymphoid cancers including Non-Hodgkins Lymphoma.
Corporate knowledge has been well documented. Internal documents from petroleum and chemical companies dating to the 1940s show awareness that benzene caused blood disorders. Companies including ExxonMobil, Shell, and various chemical manufacturers have faced litigation from workers who developed blood cancers after workplace exposure. The legal theory is typically that companies failed to provide adequate protective equipment or warning despite knowing the risks.
Agent Orange and Dioxin Exposure
Agent Orange was a tactical herbicide used by the United States military during the Vietnam War to defoliate jungle cover. The formulation contained 2,4-D and 2,4,5-T, and was contaminated with 2,3,7,8-tetrachlorodibenzodioxin, commonly known as TCDD or dioxin. Dioxin is one of the most toxic substances ever created by industrial processes.
The biological mechanism involves the aryl hydrocarbon receptor, a protein that regulates gene expression. Dioxin binds to this receptor and disrupts normal immune cell development and function. It causes oxidative stress and epigenetic changes that can lead to malignant transformation of lymphocytes. A 2003 study published in the Journal of the American Medical Association found that Vietnam veterans with the highest serum levels of TCDD had a significantly elevated risk of Non-Hodgkins Lymphoma.
The manufacturers of Agent Orange included Monsanto, Dow Chemical, Diamond Shamrock, Hercules, and others. Evidence emerged in litigation that these companies knew about dioxin contamination and its health effects but continued production. In 1991, Congress passed the Agent Orange Act which established a presumptive service connection for veterans with certain cancers including Non-Hodgkins Lymphoma. This legal presumption exists because the exposure was so well documented and the causal connection so clear.
Trichloroethylene and Other Industrial Solvents
Trichloroethylene, tetrachloroethylene (also called perchloroethylene or PERC), and other chlorinated solvents have been widely used in dry cleaning, metal degreasing, and manufacturing. These chemicals contaminate groundwater near military bases, industrial sites, and dry cleaning facilities throughout the United States.
These solvents are metabolized into reactive intermediates that cause oxidative damage and immune dysregulation. Trichloroethylene has been linked to alterations in T-cell and B-cell populations. A 2013 review in Environmental Health Perspectives evaluated occupational cohort studies and found consistent evidence of elevated Non-Hodgkins Lymphoma risk among workers with long-term solvent exposure.
The litigation involves both workplace exposure cases and groundwater contamination cases. At Camp Lejeune military base in North Carolina, drinking water was contaminated with trichloroethylene and perchloroethylene from the 1950s through the 1980s. Studies by the Agency for Toxic Substances and Disease Registry found elevated cancer rates among personnel stationed there. Congress passed the Camp Lejeune Justice Act in 2022 allowing victims to sue for damages. Dry cleaning companies have also faced liability for failing to protect workers and for environmental contamination.
Pesticides Beyond Glyphosate
Numerous other pesticides have been linked to Non-Hodgkins Lymphoma in agricultural workers and applicators. These include organophosphates like malathion and diazinon, organochlorines like DDT and lindane, and carbamate insecticides. The Agricultural Health Study, a prospective cohort study of over 50,000 pesticide applicators in Iowa and North Carolina, has documented associations between specific pesticides and lymphoid malignancies.
The mechanisms vary by chemical class but generally involve immune suppression, hormonal disruption, and genotoxicity. Organophosphates inhibit acetylcholinesterase, leading to neurological effects, but also appear to affect immune cell function. Organochlorines persist in fatty tissue and can cause long-term endocrine disruption. A 2014 meta-analysis in the International Journal of Environmental Research and Public Health found that occupational pesticide exposure was associated with a 40 percent increased risk of Non-Hodgkins Lymphoma.
Many pesticide manufacturers have faced litigation similar to the glyphosate cases. The legal issues center on failure to warn, inadequate safety testing, and suppression of unfavorable research. Documents produced in discovery have repeatedly shown that companies possessed internal studies suggesting carcinogenic potential while public statements minimized risk.
Immunosuppressive Medications
Medications that suppress the immune system increase the risk of Non-Hodgkins Lymphoma through a well-understood mechanism. When immune surveillance is weakened, malignant lymphocytes that would normally be eliminated can proliferate unchecked. This is seen most dramatically in organ transplant recipients who take immunosuppressive drugs like cyclosporine, tacrolimus, and azathioprine to prevent rejection.
A 2010 study in the Journal of the American Society of Nephrology found that kidney transplant recipients had a 20-fold increased risk of Non-Hodgkins Lymphoma compared to the general population. The risk is dose-dependent and duration-dependent. Patients with autoimmune diseases who take long-term immunosuppressive therapy also face elevated risk, though lower than transplant recipients.
This cause has no corporate wrongdoing dimension. These medications serve critical medical purposes, and patients taking them do so under physician supervision with informed consent. The mechanism is included here because it represents one of the clearest demonstrations of how immune dysfunction leads to lymphoma. If you have taken immunosuppressive medications, that exposure is part of your medical history and relevant to understanding your diagnosis.
Autoimmune Disease
Several autoimmune conditions independently increase the risk of Non-Hodgkins Lymphoma. Rheumatoid arthritis, Sjogren syndrome, systemic lupus erythematosus, and celiac disease have all been associated with elevated lymphoma risk. The mechanism involves chronic immune stimulation and inflammation.
In autoimmune disease, the immune system is chronically activated. B-cells and T-cells undergo repeated cycles of division and proliferation. Each cell division is an opportunity for DNA replication errors. Over years or decades, this increased proliferation rate raises the probability of a malignant mutation. A 2006 study in Arthritis & Rheumatism followed over 75,000 patients with rheumatoid arthritis and found they had approximately double the risk of lymphoma compared to matched controls.
There is no corporate liability here. This is human biology. The same immune dysregulation that causes the autoimmune disease also creates conditions favorable to lymphoma development. Some of the increased risk may be attributable to immunosuppressive treatments rather than the disease itself, but studies suggest the disease itself confers independent risk.
Viral Infections: Epstein-Barr, Hepatitis C, and HIV
Several viruses are established causes of Non-Hodgkins Lymphoma through direct effects on lymphocytes. Epstein-Barr virus, which causes infectious mononucleosis, infects B-cells and can drive their malignant transformation. The virus produces proteins that mimic growth signals, causing infected cells to proliferate. Certain subtypes of Non-Hodgkins Lymphoma, particularly Burkitt lymphoma and some diffuse large B-cell lymphomas, are strongly associated with Epstein-Barr infection.
Hepatitis C virus causes chronic liver inflammation but also has direct effects on lymphocytes. A 2007 meta-analysis in the International Journal of Cancer found that Hepatitis C infection was associated with a 20 to 30 percent increased risk of Non-Hodgkins Lymphoma. Successful treatment of Hepatitis C with antiviral therapy has been shown to reduce this risk.
HIV causes profound immune suppression, and before effective antiretroviral therapy became available, HIV-infected individuals had a 100-fold or greater increase in lymphoma risk. The risk has declined dramatically with modern treatment but remains elevated compared to the general population. The mechanism is loss of immune surveillance combined with chronic immune activation.
These are infectious causes with no litigation dimension. They represent the biological reality that certain pathogens alter lymphocyte biology in ways that promote cancer.
Genetic Susceptibility
Family history is a consistent risk factor for Non-Hodgkins Lymphoma. First-degree relatives of patients with lymphoma have approximately double the risk of developing lymphoid malignancies themselves. This reflects inherited genetic variants that affect immune function, DNA repair, and cellular responses to environmental exposures.
Genome-wide association studies have identified specific genetic variants associated with Non-Hodgkins Lymphoma risk. These include variants in the HLA region on chromosome 6, which regulates immune recognition, and variants in genes involved in apoptosis and B-cell development. A 2017 study in Blood identified over a dozen genetic loci associated with different lymphoma subtypes.
No single gene causes Non-Hodgkins Lymphoma in the way that BRCA mutations cause breast cancer. Instead, multiple common variants each contribute small increments of risk. The practical implication is that genetic background influences susceptibility to environmental triggers. Two people with identical exposures may have different outcomes based on their genetic variants affecting metabolism of toxins or efficiency of DNA repair.
Obesity and Metabolic Factors
Obesity has been associated with increased risk of several cancers including Non-Hodgkins Lymphoma. A 2008 meta-analysis in the British Journal of Cancer reviewed 20 studies and found that obese individuals had a 20 percent increased risk of lymphoma compared to individuals with normal body mass index.
The mechanism likely involves chronic low-grade inflammation associated with excess adipose tissue. Fat cells produce inflammatory cytokines including interleukin-6 and tumor necrosis factor alpha. These cytokines create a pro-inflammatory environment that may promote lymphocyte proliferation and survival. Obesity is also associated with insulin resistance and altered levels of growth factors that could influence cancer risk.
This is a lifestyle and metabolic factor with no corporate cause. It is included because the epidemiological evidence is consistent and the biological mechanism is plausible. If you have a history of obesity, that is one factor in your overall risk profile.
Hair Dye
Permanent hair dye, particularly darker shades used before 1980, has been studied as a potential risk factor for Non-Hodgkins Lymphoma. Older formulations contained aromatic amines including compounds that were known mutagens. Some epidemiological studies found associations between long-term use of dark permanent dyes and lymphoma risk.
A 2004 study in the American Journal of Epidemiology found that women who used dark permanent hair dyes for more than 25 years had an elevated risk of Non-Hodgkins Lymphoma. However, a 2020 meta-analysis in the International Journal of Cancer found that the association was inconsistent across studies and appeared to be limited to pre-1980 formulations.
The modern formulations have been reformulated to remove the most concerning compounds. Some litigation occurred against hair dye manufacturers, but the scientific evidence has been mixed. This represents an exposure that may have been relevant historically but appears to be less concerning with current products.
Radiation Exposure
Ionizing radiation causes DNA damage and is a known cause of multiple cancers including leukemia and lymphoma. Atomic bomb survivors in Japan showed elevated rates of Non-Hodgkins Lymphoma decades after exposure. Patients who received radiation therapy for other cancers face increased risk of secondary malignancies including lymphoma.
The mechanism is direct. High-energy radiation causes double-strand DNA breaks. If these breaks are misrepaired, chromosomal translocations can result. Specific translocations involving immunoglobulin genes or other lymphocyte regulatory genes can drive malignant transformation. A 2010 study in Radiation Research found that radiation doses above 1 Gray significantly increased lymphoma risk in a dose-dependent manner.
Medical radiation is a known risk that is accepted because the benefits of treating the primary cancer outweigh the risks. Occupational radiation exposure has been a source of litigation among nuclear workers, radiologists, and others who faced inadequate protection. Environmental radiation exposure from nuclear accidents or weapons testing has also been the subject of compensation programs.
The Pattern You Should Know About
When you examine the corporate causes of Non-Hodgkins Lymphoma, a consistent pattern emerges. In case after case, internal company documents revealed that corporations possessed data about health risks years or decades before the public knew. This was true for Monsanto and glyphosate, where emails showed awareness of unfavorable studies and strategic efforts to discredit them. It was true for chemical companies and benzene, where documents from the 1940s acknowledged that benzene caused blood disorders. It was true for Agent Orange manufacturers who knew about dioxin contamination.
The pattern is not coincidental. It reflects the economic incentives facing corporations that produce profitable products later found to be harmful. Early warning signs emerge from animal studies or epidemiological observations. Rather than conducting definitive testing or warning users, companies often choose to emphasize uncertainty, fund studies designed to produce negative results, and maintain that existing evidence is insufficient. Products remain on the market while exposure continues.
This pattern matters because it means that corporate assurances of safety cannot be taken at face value. Multiple chemicals now recognized as carcinogens were marketed as safe for decades. Regulatory approval does not guarantee safety; it reflects the evidence that was presented to regulators, which may not include all the evidence that exists. When litigation finally forces disclosure of internal documents, the gap between what companies knew and what they told the public is often vast.
If you were exposed to a corporate product that is now linked to Non-Hodgkins Lymphoma, you should understand that your exposure was not an accident of nature. It was the foreseeable result of decisions made by identifiable people who had access to data and chose profit over precaution. That is a different moral category than a genetic predisposition or a viral infection.
How to Think About Your Own Situation
Understanding the causes of Non-Hodgkins Lymphoma in the abstract is different from determining what caused your specific diagnosis. Most cancers are multifactorial, meaning multiple exposures and risk factors contributed. You may never know with certainty which factor was decisive. However, you can systematically examine your exposure history to identify likely contributors.
Start with occupational history. What jobs have you held throughout your life? Agricultural workers, landscapers, groundskeepers, golf course maintenance workers, and farmers are at high risk for pesticide exposure. Industrial workers in chemical plants, petroleum refineries, manufacturing facilities, and metal shops may have been exposed to benzene or solvents. Dry cleaning workers faced perchloroethylene exposure. Military veterans, particularly those who served in Vietnam or were stationed at contaminated bases like Camp Lejeune, have documented exposures.
For each job, try to remember what chemicals you worked with. Did you spray herbicides or pesticides? Did you mix chemicals or clean equipment? Were you provided with protective equipment like gloves, respirators, or protective clothing? Did you shower at work or bring contaminated clothing home? These details matter because they affect the intensity and duration of exposure.
Consider residential history. Have you lived near agricultural fields where pesticides were sprayed? Near industrial facilities or military bases? Have you relied on well water that could have been contaminated by industrial solvents or agricultural runoff? The Agency for Toxic Substances and Disease Registry maintains databases of contaminated sites. You can search by address to determine if you lived near a Superfund site or other recognized contamination.
Review your medical history. Have you taken immunosuppressive medications for an autoimmune condition or organ transplant? Have you been diagnosed with rheumatoid arthritis, lupus, Sjogren syndrome, or celiac disease? Have you been infected with Hepatitis C, HIV, or had severe Epstein-Barr infection? Have you received radiation therapy for another cancer? All of these are documented risk factors independent of any corporate exposure.
Examine lifestyle factors. What has been your body mass index over the years? Did you use permanent hair dye regularly, particularly dark colors before 1980? These factors contribute less to overall risk than occupational chemical exposures but are part of the complete picture.
Gather documentation. If you worked in agriculture or landscaping, try to obtain employment records that show what products were used. If you served in the military, your DD-214 discharge papers and service records are critical. If you lived near contaminated sites, maps and environmental reports may document what chemicals were present. Medical records showing diagnoses of autoimmune disease or prescriptions for immunosuppressive drugs are also relevant.
This process serves two purposes. First, it helps you understand your own illness. The question of why this happened to you deserves more than vague references to bad luck. Second, if you identify corporate exposure, it may provide a path to compensation. But that is secondary. The primary goal is to give you the clarity that comes from understanding cause and effect.
If a Corporation Caused This
If your examination of your exposure history reveals that you had substantial occupational or residential exposure to glyphosate, benzene, Agent Orange, industrial solvents, or other chemicals linked to Non-Hodgkins Lymphoma, you may have a legal claim. The legal process for these claims follows a predictable structure, and it is important to understand what it involves and what it does not.
Product liability and toxic tort claims are handled on a contingency fee basis. This means you pay no money upfront. Attorneys who handle these cases invest their own resources into investigation, expert witnesses, and litigation, and are paid a percentage of any recovery. If there is no recovery, you owe nothing. This structure exists because it allows people without financial resources to pursue claims against large corporations with extensive legal departments.
The legal standard requires proving that you were exposed to the product, that the product is capable of causing Non-Hodgkins Lymphoma, and that your exposure was a substantial factor in causing your illness. This is not a beyond-reasonable-doubt criminal standard. It is a more-likely-than-not civil standard. Causation is established through a combination of your exposure history, epidemiological studies showing increased risk, and expert medical testimony.
The process begins with consultation with an attorney experienced in toxic tort litigation. You will be asked about your diagnosis, your work history, and your exposure to specific products. Medical records will be reviewed to confirm diagnosis and rule out alternative causes. If the attorney believes the case has merit, an agreement will be signed and investigation will begin.
Discovery is the phase where internal corporate documents are obtained. This is where emails, memos, study reports, and other materials that show what the company knew are brought to light. Many of the most damaging documents in the Monsanto glyphosate litigation were discovered during this phase. Companies resist producing these documents, but court orders compel disclosure.
Expert witnesses are retained to provide opinions on causation. These are typically medical doctors, toxicologists, or epidemiologists who review the scientific literature and your specific exposure history. Their role is to explain to a jury how the exposure caused the disease. Defense experts will offer contrary opinions. The jury weighs the credibility and persuasiveness of competing experts.
Many cases settle before trial. Once discovery reveals internal documents showing corporate knowledge of risk, settlement negotiations intensify. Settlement amounts vary based on the strength of the evidence, the severity of the illness, the age of the plaintiff, and the jurisdiction. Some cases go to trial, and juries have awarded both compensatory damages for medical expenses and suffering and punitive damages to punish corporate misconduct.
The timeline is often years, not months. Toxic tort litigation is complex and document-intensive. Appeals can extend the process further. This requires patience and persistence. However, for many people, the process provides not just financial compensation but also validation. It establishes in a public forum that what happened to you was not random misfortune but the result of corporate decisions.
You should also know that there are time limits. Statutes of limitations vary by state but typically require filing within two to four years of diagnosis. If you believe you have a claim, consulting with an attorney promptly is important to preserve your rights.
Non-Hodgkins Lymphoma is a devastating diagnosis. The physical, emotional, and financial toll is immense. If a corporation caused your illness through exposure to chemicals they knew or should have known were dangerous, the legal system provides a mechanism for accountability. It is not a perfect mechanism, and it cannot restore health, but it is the tool available in a society governed by law.
If a corporation caused your Non-Hodgkins Lymphoma, that is not bad luck. That is not random chance. That is the result of decisions made by executives and scientists who had data about risks and chose to prioritize profit over human health. Internal documents from Monsanto, chemical manufacturers, and other corporations demonstrate this pattern repeatedly. Those decisions have names attached to them. Those emails have authors. That is a fundamentally different situation than a genetic mutation or a viral infection.
You deserved to know the risks before you were exposed. You deserved honest information about the products you worked with or lived near. The fact that corporations withheld that information, suppressed unfavorable research, and misled regulators is why the legal system allows you to seek compensation. It is an acknowledgment that what happened to you was preventable and that responsibility lies with those who created the risk while concealing it. Understanding that does not change your diagnosis, but it does change the meaning of your diagnosis. It provides clarity about cause and effect in a situation where you were told there were no answers. And sometimes, clarity is what makes it possible to move forward.